Christopher Ryan Sullivan Sells 8,458 Shares of Avalo Therapeutics (NASDAQ:AVTX) Stock

Avalo Therapeutics, Inc. (NASDAQ:AVTX) CFO Christopher Ryan Sullivan sold 8,458 shares of the business’s stock in a transaction that occurred on Wednesday, April 29th. The stock was sold at an average price of $13.09, for a total transaction of $110,715.22. Following the sale, the chief financial officer owned 8,880 shares of the company’s stock, valued at approximately $116,239.20. This represents a 48.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christopher Ryan Sullivan also recently made the following trade(s):

• On Thursday, April 30th, Christopher Ryan Sullivan sold 8,457 shares of Avalo Therapeutics stock. The shares were sold at an average price of $13.23, for a total transaction of $111,886.11.
• On Thursday, April 2nd, Christopher Ryan Sullivan sold 7,980 shares of Avalo Therapeutics stock. The shares were sold at an average price of $17.15, for a total transaction of $136,857.00.
• On Wednesday, April 1st, Christopher Ryan Sullivan sold 7,979 shares of Avalo Therapeutics stock. The stock was sold at an average price of $16.77, for a total transaction of $133,807.83.

Avalo Therapeutics Stock Performance

Avalo Therapeutics stock traded up $0.31 during trading on Friday, reaching $13.71. 720,705 shares of the company’s stock were exchanged, compared to its average volume of 613,175. Avalo Therapeutics, Inc. has a 52-week low of $3.39 and a 52-week high of $20.72. The firm has a market cap of $366.25 million, a price-to-earnings ratio of -2.39 and a beta of 0.93. The company’s 50-day moving average is $15.29 and its two-hundred day moving average is $16.19.

Avalo Therapeutics (NASDAQ:AVTX) last released its quarterly earnings data on Monday, March 23rd. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($1.54) by $1.17. The company had revenue of $0.06 million during the quarter, compared to analysts’ expectations of ($0.21) million. Analysts anticipate that Avalo Therapeutics, Inc. will post -4.04 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Orbimed Advisors LLC grew its stake in Avalo Therapeutics by 39.5% during the 3rd quarter. Orbimed Advisors LLC now owns 1,349,300 shares of the company’s stock valued at $17,150,000 after purchasing an additional 382,300 shares in the last quarter. Nantahala Capital Management LLC raised its position in shares of Avalo Therapeutics by 24.1% in the 3rd quarter. Nantahala Capital Management LLC now owns 1,235,000 shares of the company’s stock valued at $15,697,000 after purchasing an additional 240,000 shares in the last quarter. Affinity Asset Advisors LLC boosted its stake in shares of Avalo Therapeutics by 4.5% during the 4th quarter. Affinity Asset Advisors LLC now owns 1,051,054 shares of the company’s stock valued at $19,087,000 after buying an additional 44,837 shares during the last quarter. Caligan Partners LP boosted its stake in shares of Avalo Therapeutics by 5.8% during the 4th quarter. Caligan Partners LP now owns 881,533 shares of the company’s stock valued at $16,009,000 after buying an additional 48,200 shares during the last quarter. Finally, Balyasny Asset Management L.P. acquired a new stake in shares of Avalo Therapeutics during the third quarter worth approximately $10,390,000. Hedge funds and other institutional investors own 87.06% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently commented on AVTX. HC Wainwright raised their target price on Avalo Therapeutics from $25.00 to $40.00 and gave the company a “buy” rating in a report on Wednesday, March 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Avalo Therapeutics in a research report on Wednesday, April 8th. Wall Street Zen upgraded shares of Avalo Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Sunday, March 29th. Guggenheim started coverage on shares of Avalo Therapeutics in a research report on Monday, February 2nd. They set a “buy” rating and a $50.00 target price on the stock. Finally, BTIG Research restated a “buy” rating and issued a $40.00 target price on shares of Avalo Therapeutics in a research note on Monday, April 13th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $44.83.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.